MXC to widen product line into acne market
Published 25-AUG-2016 15:13 P.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MGC Pharma (ASX:MXC) is expanding into a market which is estimated to be worth $137 billion worldwide.
MXC told its shareholders this week that it was developing a psoriasis and acne dermatological product, based on cannabidoil (CBD) derived from cannabis plants.
MXC already has a line-up of cosmetic products with active ingredients derived from cannabis on the market, but this is a new area for the company.
It said the development of such a product would be a “substantial commercial opportunity” for the company, as it estimated the global skincare market at $137 billion.
It is likely, however, that this figure is a broad-based figure rather than a figure covering the acne, psoriasis, and seborrhoea market. Investors should always seek professional financial advice before investing.
MXC said that it had already received “favourable” microbiology results on an initial batch, which demonstrated the safety of the product when applied to skin.
It is now moving ahead to human trials of the new product line, with skin patch trials pencilled in for next month.
At the same time, it is applying for a European Cosmetic Product Notification approval which would allow it to sell the products in Europe.
MXC said the ability to access products in this line with CBD ingredients without a prescription was scant at best, meaning that it had a first-mover advantage in the marketplace.
“With tests of our CBD skin care range progressing, we are on track towards the release of a dermatologically tested product for the suffering of psoriasis, acne and seborrhoea conditions,” managing director Nativ Segev said.
“We believe this presents a tremendous commercial opportunity for the company and I look forward to presenting updates to the market as we make progress with our testing phases.”
With testing pencilled in for next month, MXC said it would be in a position to receive results in late 2016.
News of a potential new product line adds momentum for the company, which has received a string of regulatory approvals this year, with Europe, Canada and crucially the US FDA clearing its existing products for sale into the market.
MXC has a wide range of anti-aging cosmetic products on the market, where the active ingredient is CBD derived from cannabis.
It also has its eyes on pharmaceutical development, earlier this year entering into a research agreement with Sipnose to develop a medical cannabis derived treatment for acute epilepsy.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
